Heptares raises $21m in tie-up with Stanley foundation
This article was originally published in Scrip
Heptares Therapeutics, a GPCR-focused drug discovery and development company, has raised $21m in a series B financing to advance a pipeline of novel drugs directed towards clinically validated targets for the treatment of neurological and psychiatric diseases. The financing round was co-led by the Stanley Family Foundation (SFF), a leading neuroscience disease foundation, and current investor Clarus Ventures with Takeda Ventures also participating.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.